INT13545

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 1991
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.23
Pain Relevance 0.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (LTA) extracellular space (LTA) extracellular region (LTA)
cell-cell signaling (LTA)
Anatomy Link Frequency
blood 2
LTA (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 18 100.00 Very High Very High Very High
rheumatoid arthritis 3 96.80 Very High Very High Very High
Analgesic 1 92.96 High High
cINOD 2 92.04 High High
Inflammation 44 89.32 High High
substance P 1 76.80 Quite High
bradykinin 1 75.52 Quite High
Osteoarthritis 1 65.44 Quite High
Onset of action 17 60.40 Quite High
cytokine 6 24.40 Low Low
Disease Link Frequency Relevance Heat
Rhinitis 119 98.20 Very High Very High Very High
Asthma 161 97.32 Very High Very High Very High
Rheumatoid Arthritis 3 96.80 Very High Very High Very High
Arthritis 3 96.72 Very High Very High Very High
Hypersensitivity 38 95.12 Very High Very High Very High
INFLAMMATION 51 91.80 High High
Edema 8 89.04 High High
Arthropathy 1 74.28 Quite High
Chondrocalcinosis 1 66.20 Quite High
Osteoarthritis 1 65.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of LT synthesis by SASP and SP could contribute to the second line efficacy of SASP therapy in rheumatoid arthritis.
Negative_regulation (Inhibition) of Gene_expression (synthesis) of LT associated with rheumatoid arthritis
1) Confidence 0.34 Published 1991 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 1673814 Disease Relevance 0.56 Pain Relevance 0.25
It does this possibly by reducing the production of leukotriene (LT)B4 synthase and LTC4, inhibiting phospholipase A2 and LTC4 (Hamasaki et al 1996).
Negative_regulation (reducing) of Gene_expression (production) of LT
2) Confidence 0.21 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621402 Disease Relevance 1.26 Pain Relevance 0.22
In an ex vivo whole blood eicosanoid production assay, tepoxalin produces a dose-related inhibition of prostaglandin (PG) and LT production in dogs (PGF2 alpha - ED50 = 0.015 mg/kg; LTB4 - ED50 = 2.37 mg/kg) and adjuvant arthritic rats following oral administration.
Negative_regulation (inhibition) of Gene_expression (production) of LT in blood associated with arthritis
3) Confidence 0.10 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7996452 Disease Relevance 0.71 Pain Relevance 0.28
The LT modifiers comprise two pharmacologic classes of compounds, the leukotriene receptor antagonists (LTRAs) and the 5-lipoxygenase (5-LO) pathway inhibitors, or otherwise known as LT biosynthesis inhibitors.
Negative_regulation (inhibitors) of Gene_expression (biosynthesis) of LT associated with antagonist
4) Confidence 0.03 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.31 Pain Relevance 0.05
The LT modifiers comprise two pharmacologic classes of compounds, the leukotriene receptor antagonists (LTRAs) and the 5-lipoxygenase (5-LO) pathway inhibitors, or otherwise known as LT biosynthesis inhibitors.
Negative_regulation (inhibitors) of Gene_expression (biosynthesis) of LT associated with antagonist
5) Confidence 0.03 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.40 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox